J&J vaccine gets FDA emergency use approval
After receiving emergency use approval from the Federal Drug Administration, the one-dose Johnson & Johnson vaccine has become the third COVID-19 vaccination available in the country. Authorized for individuals age 18 and older, the J&J vaccine only requires one dose and can be stored at normal refrigeration temperatures, which will make widespread dissemination throughout the state and country considerably easier. An ongoing randomized, placebo-controlled study conducted in the U.S., Mexico, South Africa and some of South America, within which 19,630 participants received the vaccine and 19,691 received saline placebo, has found the vaccine was approximately 67 percent effective at least 14 days after vaccination and 66 percent effective at least 28 days after vaccination in preventing moderate to severe/critical COVID-19. When it comes to preventing strictly severe/critical COVID-19, the study showed approximately 77 percent efficacy at least 14 days after vaccination and 85 percent efficacy at least 28 days after vaccination. “This vaccine is not only highly effective against severe disease in the United States, but was also highly effective against the highly transmissible South African variant that is now showing up in the United States,” said Paul Kilgore, M.D., MPH, one of the co-principal investigators of the J&J trial at Henry Ford that began in November, and an associate professor and director of research in the Department of Pharmacy at Wayne State University, in a press release. “It is 100 percent effective in preventing hospitalizations and deaths and is also equally effective across all races, including whites, African Americans and Hispanics.”